Cancer-protective action of both RASSF1A and DIRAS3 are affected in thyroid cancer as a result of gene expression silencing [30], mainly hypermethylation in the promoter region and loss of heterozygosity [21,31], respectively. Here, RASSF1 is linked to thyroid gland carcinoma.